Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study.

By Ramachandran S. Vasan, A. Beiser, S. Seshadri, Martin G. Larson, W. Kannel, Ralph B. D’Agostino, Daniel Levy. Journal of the American Medical Association (JAMA), 2002

1,553 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Nutrition and Dietetics

View Paper: https://www.semanticscholar.org/paper/bd298434b3948d162255598f58db960c62704cd1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. G. Fonarow
2. T. Horwich
3. S. Laurent
4. C. Bushnell
5. J. Januzzi
6. C. Iadecola
7. M. Creager
8. P. Whelton

In Endocrinology, Diabetes and Metabolism

1. C. Iadecola
2. R. Eckel
3. M. Creager
4. Véronique L. Roger

In Nutrition and Dietetics

1. Richard P. Mayeux

Citations in the corpus

• Lifetime risk of symptomatic knee osteoarthritis. (2008, background): “Lifetime risk has been reported for various chronic conditions and risk factors, including coronary heart disease (6), hypertension (7), diabetes (8), and breast cancer (9).”
• 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, background): “ACE inhibitors should be used in all patients with a reduced EF to prevent symptomatic HF, even if they do not have a history of MI (65, 344).”
• 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2007, background): “Furthermore, the risk of developing hypertension is greater in subjects with high normal than in those with normal or optimal blood pressure with an additional increase in risk when, as often occurs, concurrent multiple risk factors and the metabolic syndrome are present.(31,32,69) Finally, new onse”
• Hypertension in adults across the age spectrum: current outcomes and control in the community. (2005, neutral): “(%) 297 (10) 693 (24) 123 (19) 176 (5) 494 (14) 106 (8)”
• Guidelines for the Primary Prevention of Stroke (2011, positive): “Individuals who are normotensive at 55 years of age have a 90% lifetime risk for developing hypertension.(227) More than two thirds of people ≥65 years of age are hypertensive.”
• 2007 ESH‐ESC Guidelines for the management of arterial hypertension (2007, methodology): “(31,32,69) Finally, new onset hypertension can be delayed by some time by administration of an antihypertensive agent.”